Pulmonx (LUNG) News Today

Pulmonx Corporation (NASDAQ:LUNG) has seen a flurry of analyst updates over the past two days. While some firms maintain bullish upside projections, others have trimmed price targets or downgraded the stock, driving volatility in LUNG shares.

• Positive Sentiment: Lake Street Capital lowered its price target on Pulmonx from $12.00 to $8.00 but maintained a buy rating, implying about a 400% upside. Lake Street Capital Lowers PT
• Positive Sentiment: D. Boral Capital trimmed its Pulmonx price target from $17.00 to $16.00 while keeping a buy rating, suggesting nearly 900% upside. Pulmonx Given New $16.00 Price Target
• Neutral Sentiment: Wells Fargo lowered its price target on Pulmonx to $3.00 and assigned an equal weight rating, indicating a potential 87.5% upside. Wells Fargo Lowers PT
• Neutral Sentiment: Analysts’ consensus recommendation on Pulmonx remains a “Moderate Buy” based on eight analysts’ ratings. Consensus Rating of Moderate Buy
• Neutral Sentiment: Summary of broad analyst expectations for Pulmonx’s future across ratings. Analyst Expectations For Pulmonx's Future
• Negative Sentiment: Piper Sandler downgraded Pulmonx from overweight to neutral and cut its price objective to $2.50. Pulmonx Rating Lowered to Neutral
• Negative Sentiment: Piper Sandler’s downgrade weighed on LUNG despite a Q2 beat, triggering a share slump. Pulmonx Slumps Despite Q2 Beat
• Negative Sentiment: Stifel Nicolaus slashed its price target on Pulmonx from $16.00 to $5.00, though it retained a buy rating, signaling lowered growth expectations. Stifel Nicolaus Cuts Price Target

Overall, Pulmonx shares have reacted to mixed signals: significant upside forecasts from some buy-side analysts are being offset by downgrades and steep target cuts from others. Investors should watch for upcoming clinical or financial catalysts that could resolve the divergence in outlooks.